- The AUGMENTSMSM Treatment: Physician Reported Outcomes of the Initial Global Patient Experience
- Journal of Fertilization: In Vitro - IVF-Worldwide, Reproductive Medicine, Genetics and Stem Cell Biology, August 14, 2015
- Michael H Fakih1, Mohamad El Shmoury2, Julia Szeptycki2, Dennis B dela Cruz2, Caroline Lux2, Suleman Verjee3, Colleen M Burgess4, Gabriel M Cohn4 and Robert F Casper2
- Author(s) affiliation:
- 1Fakih IVF, Dubai, UAE
2TCART Fertility Partners, Toronto, ON M5S 2X9, Canada
3Versante International, LLC Oakland, CA 94606, USA
4OvaScience Cambridge, MA 02421, USA
- Short description:
- Infertility treatment prior to 1978 proved challenging to both patients and their physicians. The birth of Louise Brown through in vitro fertilization (IVF) was the result of decades-long research in both the basic and clinical sciences and followed hundreds of failed attempts at human IVF . With IVF’s successful introduction, related and supportive technologies soon emerged including IVF and the use of donor eggs, cryopreservation and frozen embryo transfer (FET), gamete intra-fallopian transfer (GIFT), zygote intra-fallopian transfer (ZIFT), intra-cytoplasmic sperm injection (ICSI) and less invasive procedures aided by enhancements in equipment, such as transvaginal ultrasound guided oocyte retrieval. It may be hard to recall now that technologies such as IVF, the use of donor eggs, and ICSI were, at first, controversial but so successful in improving outcomes that they were most often adopted into clinical practice without any demonstrated benefit in randomized controlled clinical trials .
- Link to the journal
Abstract taken from PubMed
- Egg precursor cells can be readily isolated from the protective outer lining of the ovarian cortex. Studies have demonstrated that mitochondria isolated from these cells are of high quality. The AUGMENTSM treatment is a proprietary new technology based on previous clinical use demonstrating that the addition of mitochondria during in vitro fertilization (IVF) is safe, improves embryo quality, and increases the success of IVF. Subsequent published animal studies also confirmed the role of mitochondria in improved outcomes. This report represents the earliest global observations of the AUGMENTSM treatment in routine clinical practice from two distinct international centers.
- Methods and results:
- The AUGMENTSM treatment was initially used in a population of difficult-to-treat patients with a poor prognosis for success with standard IVF who were likely moving to donor egg as a next step. Each group reported marked improvements in pregnancy rates above the historic IVF success rate for these patients (e.g., 11- and 18- fold increase in ongoing clinical pregnancy rates in the UAE and Canada, respectively). In a 25 patient subset, retrieved eggs from each woman were allocated to two treatment groups; one group underwent the AUGMENTSM treatment at the time of ICSI while the other group underwent conventional ICSI. Embryos were selected for fresh-embryo transfer based on standard criteria including embryo morphology and the results of preimplantation genetic testing. Morphogenetic embryo selection and transfer from the AUGMENTSM treatment group was significantly higher, suggesting that improved embryo quality may have resulted in the improved pregnancy rates observed in these women.
- Based on these findings, the AUGMENTSM treatment may be a viable treatment option to address an unmet need for women with poor reproductive histories, history of poor egg quality, poor embryo development, previously failed IVF, and those seeking—despite repeated failures-to conceive genetically-related offspring.
- Link to the paper on PubMed